{"id":"standard-interval-dosing","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Standard interval dosing is a pharmaceutical administration strategy where a drug is given at consistent, predetermined time intervals (e.g., every 8 hours, once daily) rather than as-needed or adaptive dosing. This approach maintains relatively steady-state drug concentrations and is the most common dosing paradigm in clinical practice. It is not a specific drug but rather a dosing methodology that can be applied to any pharmaceutical agent.","oneSentence":"Standard interval dosing is a dosing schedule approach rather than a drug itself, referring to the administration of medications at regular, fixed time intervals.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:38:12.142Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT05593497","phase":"PHASE2","title":"A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2024-05-31","conditions":"High-Risk Prostate Cancer","enrollment":30},{"nctId":"NCT04307576","phase":"PHASE3","title":"A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia","status":"RECRUITING","sponsor":"Mats Heyman","startDate":"2020-07-13","conditions":"Leukemia, Acute Lymphoblastic","enrollment":6430},{"nctId":"NCT04781387","phase":"PHASE2","title":"Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection","status":"COMPLETED","sponsor":"Crestone, Inc","startDate":"2021-01-05","conditions":"Clostridioides Difficile Infection","enrollment":43},{"nctId":"NCT07285460","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-12-18","conditions":"Hemophilia","enrollment":85},{"nctId":"NCT07497607","phase":"PHASE2","title":"Reduced Elective Nodal and CTV Dose for HPV+ Oropharyngeal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sara Medek","startDate":"2026-06-01","conditions":"Oropharyngeal Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma","enrollment":31},{"nctId":"NCT07462663","phase":"","title":"SHAPE-ENDO: Multimodal Pre-Surgical Optimization in Patients With Obesity and Early-Stage Endometrial Cancer","status":"NOT_YET_RECRUITING","sponsor":"Hospital Universitari de Bellvitge","startDate":"2026-05","conditions":"Endometrial Cancer, Endometrial Cancer Stage I, Atypical Endometrial Hyperplasia and Endometrial Carcinoma Stage I","enrollment":82},{"nctId":"NCT07487077","phase":"PHASE4","title":"Extended Dosing Intervals Trial for Oral Cholera Vaccine, Kenya","status":"RECRUITING","sponsor":"Albert B. Sabin Vaccine Institute","startDate":"2025-10-31","conditions":"Cholera Vaccination","enrollment":1071},{"nctId":"NCT04532047","phase":"PHASE1","title":"PEARL (PrEnAtal Enzyme Replacement Therapy for Lysosomal Storage Disorders)","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2021-07-01","conditions":"MPS I, MPS II, MPS IVA","enrollment":10},{"nctId":"NCT02287428","phase":"PHASE1","title":"Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2014-11","conditions":"Glioblastoma","enrollment":56},{"nctId":"NCT07467590","phase":"PHASE2","title":"Combination of High and Low-Dose Radiotherapy With Immune Therapy and TKI in Advanced Colorectal Cancer: A Phase II Study","status":"NOT_YET_RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2026-04-01","conditions":"Refractory Colorectal Cancer, Radiotherapy-Induced Immune Priming, Immune Response","enrollment":33},{"nctId":"NCT07463599","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma","status":"RECRUITING","sponsor":"HonorHealth Research Institute","startDate":"2026-02-17","conditions":"Metastatic Colorectal Carcinoma (mCRC), Colorectal Cancer (CRC), Adenomatous Polyposis Coli (APC) Gene Mutation","enrollment":126},{"nctId":"NCT04974099","phase":"PHASE2, PHASE3","title":"Personalized Infliximab Induction Strategy With Model-informed Dosing in Patients With Crohn's Disease","status":"TERMINATED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2021-10-01","conditions":"Crohn Disease","enrollment":6},{"nctId":"NCT06216249","phase":"PHASE2","title":"Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2024-08-01","conditions":"Prostate Carcinoma, Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) v8","enrollment":90},{"nctId":"NCT07460349","phase":"","title":"Extended Interval Dosing of Gentamicin in Neonates","status":"NOT_YET_RECRUITING","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2026-03","conditions":"Early Onset Sepsis","enrollment":42},{"nctId":"NCT07457099","phase":"","title":"Impact of Postoperative Radiotherapy Versus PD-1 Inhibitor Maintenance on Survival in Resectable Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Zhujiang Hospital","startDate":"2026-04-01","conditions":"Locally Advanced Oral Squamous Cell Carcinoma, Locally Advanced Oropharyngeal Squamous Cell Carcinoma","enrollment":85},{"nctId":"NCT06398106","phase":"PHASE4","title":"Proactive TDM Versus Standard Use of Biologics in Psoriasis","status":"RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2024-12-20","conditions":"Psoriasis Vulgaris","enrollment":210},{"nctId":"NCT07444060","phase":"","title":"Guselkumab Vs Ustekinumab in Stricturing Crohn's Disease","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-03-01","conditions":"CD - Crohn's Disease, Stricture; Bowel, IBD - Inflammatory Bowel Disease","enrollment":100},{"nctId":"NCT07210632","phase":"EARLY_PHASE1","title":"Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)","status":"NOT_YET_RECRUITING","sponsor":"Eben Rosenthal","startDate":"2026-03-30","conditions":"Brain Cancer, HGG, Glioma","enrollment":38},{"nctId":"NCT04469530","phase":"PHASE2","title":"Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors","status":"RECRUITING","sponsor":"Emory University","startDate":"2020-09-16","conditions":"Solid Tumor","enrollment":55},{"nctId":"NCT07408947","phase":"","title":"Clinical Severity in Scorpion Envenomation: Home Remedies, Delay to Medical Care, and Antivenom Dosing Strategies in an Emergency Department","status":"COMPLETED","sponsor":"University of Guadalajara","startDate":"2025-08-07","conditions":"Scorpion Envenomation","enrollment":3145},{"nctId":"NCT07403591","phase":"NA","title":"Mapsd Dual-target cTBS (Auditory Cortex and M1) for Generalized Anxiety Disorder","status":"NOT_YET_RECRUITING","sponsor":"Anhui Medical University","startDate":"2026-03-01","conditions":"Generalized Anxiety Disorder","enrollment":60},{"nctId":"NCT07401537","phase":"PHASE2","title":"Efficacy and Safety of Extended-Dose Interval Immunotherapy Versus Standard-Dose Interval Immunotherapy for Advanced Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-12-31","conditions":"Triple -Negative Breast Cancer, Breast Cancer","enrollment":416},{"nctId":"NCT07287332","phase":"NA","title":"BLOOM: Pragmatic Feasibility Trial","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2026-01-15","conditions":"Sepsis, Infection","enrollment":300},{"nctId":"NCT05049512","phase":"NA","title":"Low Dose Multi-Nut Oral Immunotherapy in Pre-schoolers With a Multi-Nut Allergy","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","startDate":"2021-11-16","conditions":"Allergy, Nut","enrollment":12},{"nctId":"NCT06897839","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Zelpultide Alfa in Preterm Neonates at High Risk of Developing Bronchopulmonary Dysplasia (BPD)","status":"RECRUITING","sponsor":"Airway Therapeutics, Inc.","startDate":"2025-02-03","conditions":"Bronchopulmonary Dysplasia","enrollment":366},{"nctId":"NCT05561725","phase":"PHASE4","title":"Perioperative Steroid Dosing on the APR in AIS","status":"RECRUITING","sponsor":"Emory University","startDate":"2023-01-03","conditions":"Adolescent Idiopathic Scoliosis (AIS)","enrollment":50},{"nctId":"NCT06440629","phase":"PHASE4","title":"Effect of Proactive Therapeutic Drug Monitoring on Maintenance of Sustained Disease Control in Adults With Rheumatoid Arthritis on a Subcutaneous TNF Inhibitor: The Rheumatoid Arthritis Therapeutic DRUg Monitoring Trial (RA-DRUM)","status":"RECRUITING","sponsor":"Diakonhjemmet Hospital","startDate":"2024-08-20","conditions":"Rheumatoid Arthritis","enrollment":350},{"nctId":"NCT06911489","phase":"PHASE1","title":"Safety Trial of 68Ga/177Lu-NRT6020 in FAP-Positive Advanced Solid Tumor Patients","status":"RECRUITING","sponsor":"Chengdu New Radiomedicine Technology Co. LTD.","startDate":"2025-11-29","conditions":"Solid Tumor Malignancy","enrollment":132},{"nctId":"NCT07379424","phase":"PHASE2","title":"A Single-arm, Phase II, Multi-center Clinical Trial of Sintilimab During the Perioperative Period in Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"chen chao Professor","startDate":"2026-01-28","conditions":"Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma","enrollment":37},{"nctId":"NCT04986254","phase":"","title":"PNEUmonia DOSing in Critically Ill Patients (PNEUDOS)","status":"COMPLETED","sponsor":"The University of Queensland","startDate":"2019-10-17","conditions":"Pneumonia","enrollment":179},{"nctId":"NCT07358845","phase":"","title":"Hematological Profiles of Preterm Infants and the Impact of Antenatal Steroids","status":"COMPLETED","sponsor":"Princess Anna Mazowiecka Hospital, Warsaw, Poland","startDate":"2011-01-02","conditions":"Haematology","enrollment":1048},{"nctId":"NCT06238895","phase":"PHASE4","title":"Optimizing Dosing Strategies in Oral Iron Supplementation","status":"COMPLETED","sponsor":"Luzerner Kantonsspital","startDate":"2024-03-01","conditions":"Iron Deficiencies, Iron Deficiency Anemia, Iron Deficiency Anemia Treatment","enrollment":29},{"nctId":"NCT07235202","phase":"PHASE1, PHASE2","title":"A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After First-line Therapy","status":"RECRUITING","sponsor":"Shenzhen Majory Biotechnology Co., Ltd.","startDate":"2025-12-24","conditions":"Pancreatic Ductal Adenocarcinoma (PDAC)","enrollment":45},{"nctId":"NCT07058155","phase":"PHASE4","title":"Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease","status":"RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2025-12-17","conditions":"Liver Cirrhoses, Portal Hypertension Related to Cirrhosis, Severe Obesity","enrollment":70},{"nctId":"NCT06919666","phase":"PHASE1, PHASE2","title":"NT219 Combined With Standard of Care Biologic Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2025-06-12","conditions":"Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma","enrollment":29},{"nctId":"NCT06441331","phase":"PHASE1","title":"Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors","status":"RECRUITING","sponsor":"ITM Solucin GmbH","startDate":"2025-09-26","conditions":"Somatostatin Receptor Positive, NETs, Lymphoma","enrollment":20},{"nctId":"NCT05564650","phase":"PHASE1","title":"Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2023-01-12","conditions":"Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome","enrollment":6},{"nctId":"NCT05859074","phase":"PHASE1","title":"A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-05-04","conditions":"Cutaneous Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma, Basal Cell Carcinoma","enrollment":56},{"nctId":"NCT04713657","phase":"PHASE1","title":"Beta-blocker Administration for Cardiomyocyte Division","status":"RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2022-12-16","conditions":"Tetralogy of Fallot, Double Outlet Right Ventricle","enrollment":40},{"nctId":"NCT05690841","phase":"PHASE3","title":"FocaL Mass Drug Administration for Vivax Malaria Elimination","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2024-10-14","conditions":"Plasmodium Vivax Malaria, Malaria","enrollment":7530},{"nctId":"NCT06831526","phase":"EARLY_PHASE1","title":"Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2025-11-06","conditions":"Glioblastoma","enrollment":12},{"nctId":"NCT01223248","phase":"PHASE3","title":"Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2010-10","conditions":"Melanoma, Ovarian Cancer, Sarcoma","enrollment":220},{"nctId":"NCT04777201","phase":"PHASE3","title":"A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2021-04-19","conditions":"Neovascular Age-related Macular Degeneration","enrollment":1036},{"nctId":"NCT05508074","phase":"PHASE2","title":"Treatment Combining Riluzole and IFB-088 in Bulbar Amyotrophic Lateral Sclerosis (TRIALS Protocol)","status":"COMPLETED","sponsor":"InFlectis BioScience","startDate":"2022-12-02","conditions":"Amyotrophic Lateral Sclerosis, ALS","enrollment":51},{"nctId":"NCT04295863","phase":"PHASE1","title":"Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2020-06-25","conditions":"Metastatic Cancer","enrollment":264},{"nctId":"NCT07190027","phase":"PHASE1, PHASE2","title":"Immunodynamics-Guided Optimization of Individualized Immunochemotherapy in Advanced Driver-Negative NSCLC: A Randomized Trial","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2025-11","conditions":"Advanced Non-Small Cell Lung Cancer (NSCLC)","enrollment":246},{"nctId":"NCT07187583","phase":"PHASE4","title":"Tapering of Biologics in Chronic Rhinosinusitis With Nasal Polyps","status":"RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2025-06-05","conditions":"Chronic Rhinosinusitis With Nasal Polyps","enrollment":135},{"nctId":"NCT06737380","phase":"PHASE1","title":"UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients","status":"RECRUITING","sponsor":"LiveKidney.Bio","startDate":"2025-01-07","conditions":"SLE, Lupus, Systemic Lupus Erthematosus","enrollment":10},{"nctId":"NCT05387603","phase":"PHASE3","title":"Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors.","status":"RECRUITING","sponsor":"Lund University Hospital","startDate":"2022-11-01","conditions":"Neuroendocrine Tumors","enrollment":300},{"nctId":"NCT07143201","phase":"PHASE2","title":"Precision Dosing of Oral Ibuprofen for PDA, A Pilot RCT","status":"RECRUITING","sponsor":"Hamilton Health Sciences Corporation","startDate":"2024-07-04","conditions":"Patent Ductus Arteriosus, Preterm","enrollment":26},{"nctId":"NCT04757636","phase":"PHASE3","title":"OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD)","status":"TERMINATED","sponsor":"Opthea Limited","startDate":"2021-03-12","conditions":"Neovascular Age-related Macular Degeneration","enrollment":998},{"nctId":"NCT04891640","phase":"NA","title":"Biologic Abatement and Capturing Kids' Outcomes and Flare Frequency in Juvenile Spondyloarthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Hospital of Philadelphia","startDate":"2021-11-11","conditions":"Juvenile Spondyloarthritis","enrollment":164},{"nctId":"NCT04278690","phase":"NA","title":"Supporting Safe Use of Medications by Parents After Infant Discharge From the Neonatal Intensive Care Unit","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2021-03-10","conditions":"Medication Administered in Error","enrollment":425},{"nctId":"NCT07091994","phase":"PHASE4","title":"A Prospective, Multicentre, Randomized Controlled Trial of Edaravone Dexborneol in Acute Ischemic Stroke With Active Malignancy","status":"NOT_YET_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2025-08-01","conditions":"Ischemic Stroke, Acute, Active Malignancies","enrollment":144},{"nctId":"NCT07088549","phase":"NA","title":"Intermittent Versus Continuous Glucose Monitoring in Intensive Care Unit","status":"NOT_YET_RECRUITING","sponsor":"University Medical Centre Ljubljana","startDate":"2025-07","conditions":"Critical Illness, Hyperglycaemia, Hypoglycaemia","enrollment":200},{"nctId":"NCT04757610","phase":"PHASE3","title":"OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)","status":"TERMINATED","sponsor":"Opthea Limited","startDate":"2021-03-12","conditions":"Neovascular Age-related Macular Degeneration","enrollment":986},{"nctId":"NCT07041801","phase":"PHASE1, PHASE2","title":"Treatment of Systemic Lupus Erythematosus With Human Umbilical Cord Mesenchymal Stem Cells","status":"RECRUITING","sponsor":"Shenzhen Beike Bio-Technology Co., Ltd.","startDate":"2025-06-28","conditions":"Systemic Lupus Erythematosus (SLE)","enrollment":58},{"nctId":"NCT03718234","phase":"PHASE1","title":"Subcutaneous Hydrocortisone Children With Congenital Adrenal Hyperplasia","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2019-01-01","conditions":"Congenital Adrenal Hyperplasia, Hyperplasia, Adrenal Hyperplasia","enrollment":11},{"nctId":"NCT05589818","phase":"PHASE2","title":"Pembrolizumab for Advanced NSCLC and PS 2-3","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2023-05-26","conditions":"Non-Small Cell Lung Cancer (NSCLC)","enrollment":45},{"nctId":"NCT04548843","phase":"PHASE1","title":"A First in Human Study to Evaluate the Safety of Infusion of MNV-BM-PLC (Autologous CD34+ Cells Enriched With Placenta Derived Allogeneic Mitochondria) in Patients With Primary Mitochondrial Diseases Associated With Mitochondrial DNA Mutation or Deletion","status":"WITHDRAWN","sponsor":"Minovia Therapeutics Ltd.","startDate":"2022-03-01","conditions":"Primary Mitochondrial Diseases","enrollment":""},{"nctId":"NCT03605901","phase":"PHASE2","title":"Dosing of Methadone for Spine Surgery","status":"TERMINATED","sponsor":"University of Florida","startDate":"2019-03-19","conditions":"Pain, Postoperative","enrollment":36},{"nctId":"NCT05851924","phase":"PHASE2","title":"A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-05-12","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":60},{"nctId":"NCT05827796","phase":"PHASE1, PHASE2","title":"IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"InxMed (Shanghai) Co., Ltd.","startDate":"2022-12-08","conditions":"Pancreatic Cancer","enrollment":70},{"nctId":"NCT05045950","phase":"PHASE2","title":"Optimizing Neurocognition With Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2021-11-17","conditions":"Brain Metastases","enrollment":53},{"nctId":"NCT06939829","phase":"PHASE4","title":"A Multicenter Clinical Study on the Continuous vs. Intermittent Infusion of Ceftazidime-Avibactam in Critically Ill Patients With Severe Infections","status":"NOT_YET_RECRUITING","sponsor":"Southeast University, China","startDate":"2025-05-01","conditions":"Patients With Critically Ill Infections","enrollment":1200},{"nctId":"NCT04708041","phase":"PHASE3","title":"Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-03-15","conditions":"Papillomavirus Infections","enrollment":700},{"nctId":"NCT06536413","phase":"PHASE1, PHASE2","title":"ATRA and Carfilzomib in Plasma Cell Myeloma Patients","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2024-07-29","conditions":"Multiple Myeloma","enrollment":42},{"nctId":"NCT05495295","phase":"PHASE1","title":"First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours","status":"RECRUITING","sponsor":"Phost'In Therapeutics","startDate":"2022-07-18","conditions":"Malignant Tumor, Advanced Solid Tumor, Glioblastoma Multiforme","enrollment":149},{"nctId":"NCT04751786","phase":"PHASE1","title":"Dose Escalation Study of Immunomodulatory Nanoparticles","status":"ACTIVE_NOT_RECRUITING","sponsor":"Radboud University Medical Center","startDate":"2021-01-11","conditions":"Advanced Solid Tumor","enrollment":15},{"nctId":"NCT03397108","phase":"","title":"Assessing the Drug Exposure Risk of Infants Breastfed by Women With Inflammatory Bowel Disease","status":"COMPLETED","sponsor":"The Hospital for Sick Children","startDate":"2017-08-31","conditions":"Crohn's Disease, Ulcerative Colitis, Healthy Controls","enrollment":79},{"nctId":"NCT06422403","phase":"PHASE2","title":"A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers","status":"RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2024-11-25","conditions":"Carcinoma, Hepatocellular, Gastric Adenocarcinoma, GastroEsophageal Cancer","enrollment":360},{"nctId":"NCT03802747","phase":"PHASE1","title":"Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases","status":"WITHDRAWN","sponsor":"University of Colorado, Denver","startDate":"2019-08","conditions":"Colorectal Cancer","enrollment":""},{"nctId":"NCT03009058","phase":"PHASE1, PHASE2","title":"Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer","status":"TERMINATED","sponsor":"Immodulon Therapeutics Ltd","startDate":"2017-05-31","conditions":"Metastatic Cancer","enrollment":2},{"nctId":"NCT04691843","phase":"PHASE3","title":"Iron Supplementation and Neurodevelopmental Outcome in ELGANs","status":"COMPLETED","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","startDate":"2021-02-01","conditions":"Iron-deficiency","enrollment":51},{"nctId":"NCT05667298","phase":"PHASE1","title":"Organ-Preserving Endoscopic Resection & Adjuvant RADIO-immuno-chemotherapy for Esophageal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Manitoba","startDate":"2023-03-01","conditions":"Esophageal Cancer","enrollment":11},{"nctId":"NCT05701423","phase":"","title":"A Study of End of Dose Phenomena in Subcutaneous Natalizumab Treated Multiple Sclerosis (MS) Participants","status":"TERMINATED","sponsor":"Biogen","startDate":"2023-02-08","conditions":"Multiple Sclerosis","enrollment":34},{"nctId":"NCT04921670","phase":"","title":"Infliximab Proactive Drug Monitoring in the Pediatric IBD Population","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cares, Kristen, M.D.","startDate":"2021-03-12","conditions":"Inflammatory Bone Disease","enrollment":60},{"nctId":"NCT03689972","phase":"PHASE3","title":"A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration","status":"COMPLETED","sponsor":"Biogen","startDate":"2018-11-27","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":585},{"nctId":"NCT05803148","phase":"NA","title":"Treatment Strategy of Vasovagal Syncope","status":"RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2023-04-05","conditions":"Syncope, Vasovagal","enrollment":184},{"nctId":"NCT01505569","phase":"NA","title":"Auto Transplant for High Risk or Relapsed Solid or CNS Tumors","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2011-10-20","conditions":"Ewing's Family Tumors, Renal Tumors, Hepatoblastoma","enrollment":44},{"nctId":"NCT05115903","phase":"PHASE4","title":"Biologic Tapering Study of TNF Inhibitors in Axial Spondyloarthritis","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2021-12-01","conditions":"Axial Spondyloarthritis","enrollment":15},{"nctId":"NCT05220462","phase":"PHASE3","title":"Remimazolam vs Midazolam Cognitive and Motor Recovery After Intravenous Conscious Sedation for Dental Extractions.","status":"UNKNOWN","sponsor":"Guy's and St Thomas' NHS Foundation Trust","startDate":"2022-03-09","conditions":"Tooth Extraction","enrollment":128},{"nctId":"NCT04359004","phase":"NA","title":"A Study to Evaluate the Effect of Vagus Nerve Stimulation in Patients Undergoing VT Ablation","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2020-12-08","conditions":"Arrhythmia, Ventricular Tachycardia (VT)","enrollment":5},{"nctId":"NCT05293938","phase":"","title":"A Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients","status":"WITHDRAWN","sponsor":"Intercept Pharmaceuticals","startDate":"2022-03-28","conditions":"Primary Biliary Cholangitis","enrollment":""},{"nctId":"NCT04203901","phase":"PHASE2","title":"Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma","status":"TERMINATED","sponsor":"CoImmune","startDate":"2020-07-22","conditions":"Advanced Renal Cell Carcinoma","enrollment":16},{"nctId":"NCT06013670","phase":"NA","title":"Standard Therapy and TIPS for Moderate to High-risk Esophageal and Gastric Variceal Bleeding","status":"RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2023-01-01","conditions":"Portal Hypertension","enrollment":86},{"nctId":"NCT02755597","phase":"PHASE3","title":"A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-07-11","conditions":"Relapsed/Refractory Multiple Myeloma","enrollment":291},{"nctId":"NCT05280405","phase":"PHASE4","title":"Early Proactive Therapeutic Drug Monitoring of Infliximab in Children: EPIC Study","status":"UNKNOWN","sponsor":"IRCCS Burlo Garofolo","startDate":"2022-03-09","conditions":"Inflammatory Bowel Diseases","enrollment":86},{"nctId":"NCT03762473","phase":"PHASE2","title":"Conversion to Envarsus Post Kidney Transplant Protects Against BK Infection","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2019-05-09","conditions":"Renal Transplant Infection","enrollment":89},{"nctId":"NCT04335370","phase":"","title":"Pharmacokinetics of Polymyxin B in Adult Patients With Cystic Fibrosis","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2019-01-09","conditions":"Cystic Fibrosis, Polymyxin B","enrollment":9},{"nctId":"NCT04502433","phase":"PHASE2","title":"Poractant Alfa (Curosurf®)) -- Effect in Adult Patients Diagnosed With 2019 Novel Coronavirus (SARS-COV-19; (Covid-19)) Acute Respiratory Distress Syndrome (ARDS)","status":"TERMINATED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2021-01-06","conditions":"Acute Respiratory Distress Syndrome","enrollment":22},{"nctId":"NCT03769311","phase":"PHASE2","title":"Cetuximab in Head and Neck Cancer Patients","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2019-04-17","conditions":"Head and Neck Cancer, Squamous Cell Carcinoma","enrollment":15},{"nctId":"NCT04225312","phase":"PHASE4","title":"Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis","status":"UNKNOWN","sponsor":"Amsterdam UMC, location VUmc","startDate":"2020-02-03","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":300},{"nctId":"NCT03548467","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Safety and Efficacy of Multiple Dosing With VB10.NEO and Bempegaldesleukin (NKTR-214) Immunotherapy in Patients With Locally Advanced or Metastatic Cancer","status":"COMPLETED","sponsor":"Nykode Therapeutics ASA","startDate":"2018-04-04","conditions":"Locally Advanced or Metastatic Solid Tumours","enrollment":41},{"nctId":"NCT05220748","phase":"PHASE1","title":"RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced CuSCC and HNSCC","status":"WITHDRAWN","sponsor":"Rakuten Medical, Inc.","startDate":"2022-03-24","conditions":"Cutaneous Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma","enrollment":""},{"nctId":"NCT04513314","phase":"PHASE4","title":"Valproate Alone or in Combination With Quetiapine for Severe COVID-19 Pneumonia With Agitated Delirium","status":"WITHDRAWN","sponsor":"University of Miami","startDate":"2023-03-28","conditions":"Covid19, Hyperactive Delirium, Pneumonia, Viral","enrollment":""},{"nctId":"NCT05594121","phase":"PHASE4","title":"Monthly Versus Daily Buprenorphine Formulations for Treatment of Opiate Use Disorder","status":"UNKNOWN","sponsor":"Royal Victoria Hospital, Canada","startDate":"2022-12","conditions":"Moderate to Severe Opioid Use Disorder","enrollment":90},{"nctId":"NCT03172377","phase":"PHASE4","title":"Lengthening Adalimumab Dosing Interval in Quiescent Crohn's Disease Patients","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2017-05-03","conditions":"Crohn Disease in Remission, Crohn Disease","enrollment":174},{"nctId":"NCT04333914","phase":"PHASE2","title":"Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection","status":"COMPLETED","sponsor":"Centre Leon Berard","startDate":"2020-04-15","conditions":"SARS-CoV-2 (COVID-19) Infection, Advanced or Metastatic Hematological or Solid Tumor","enrollment":19},{"nctId":"NCT04132388","phase":"PHASE4","title":"Hidradenitis Suppurativa Patient Experience With Humira Treatment","status":"WITHDRAWN","sponsor":"Wake Forest University Health Sciences","startDate":"2020-08-20","conditions":"Hidradenitis Suppurativa","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":57,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["SID"],"phase":"marketed","status":"active","brandName":"Standard interval dosing","genericName":"Standard interval dosing","companyName":"Amsterdam UMC, location VUmc","companyId":"amsterdam-umc-location-vumc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}